retatrutide and autoimmune disease Weight loss with as compared to licenced obesity Retatrutide (LY-3437943) Market Analysis, 2033:

Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: a consensus statement from the association of Anaesthetists, association of British clinical Diabetologists, British obesity and metabolic surgery society, centre for perioperative care, joint British diabetes societies for inpatient care, Royal College of Anaesthetists, society for obesity and bariatric anaesthesia and UK clinical pharmacy association

The litigation currently remains in the discovery phase, with both sides exchanging documents, relevant medical records, and expert reports

The right timing depends on why you are stopping

If youre taking GLP-1 medications and pregnancy is on your mind, timing matters

Accessed March 9, 2026.